Explore the HER2CLIMB-05 study's findings on tucatinib's impact on breast cancer progression-free survival, enhancing treatment options for pharmacists.
Sarah Cannon Research Institute | Strategic Alliance Partners
Latest from Sarah Cannon Research Institute
Vepdegestrant was the first PROTAC to be evaluated in a phase 3 clinical trial.
Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Clinical Manifestations and Prognostic Impact of Anemia in Myelofibrosis
2
Understanding Myelofibrosis and the Central Role of JAK Pathway Dysregulation
3
Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy
4
Pharmacists’ Expanding Role in Optimizing Oral Endocrine and Targeted Breast Cancer Therapies
5